A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease.
Phase of Trial: Phase IV
Latest Information Update: 20 Dec 2016
At a glance
- Drugs Arformoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms LSSS
- Sponsors Sunovion Pharmaceuticals
- 20 Dec 2016 Results assessing changes in health status after adding arformoterol tartrate or placebo to patients treatment regimens, published in the Clinical Therapeutics journal.
- 16 May 2016 Post-hoc analyses results published in the Media Release
- 04 May 2016 Post-hoc analyses presented at the 2016 American Thoracic Society (ATS) International Conference, according to a Sunovion Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History